登录
Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case [0.03%] 寡转移BRAF V600E突变型结直肠癌的治疗：从一例临床病例分析中学习
Renato Maria Marsicano,Luca Boscolo Bielo,Elena Guerini Rocco et al. Renato Maria Marsicano et al.
Q33.32024 Case Reports Clinical colorectal cancer. 2025 Mar 25:S1533-0028(25)00030-1. DOI:10.1016/j.clcc.2025.03.003 2025
Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab [0.03%] 西妥昔单抗治疗转移性结直肠癌患者中ctDNA RAS突变的预后价值
Seong-Eun Kim,Ji Sung Lee,Sun Young Kim et al. Seong-Eun Kim et al.
Background: RAS mutations are important biomarkers for predicting the efficacy of anti-EGFR treatment in metastatic colorectal cancer (mCRC). The emergence of RAS mutations is a known resistance mechanism. This study aime...
Circulating Tumor DNA in Addition to Fecal Immunochemical Test in a Dual-Test Colorectal Cancer Screening Approach [0.03%] 联合粪便免疫化学检测的循环肿瘤DNA在结直肠癌筛查中的应用研究
Caroline L Kahn,Mathias M Petersen,Jakob Kleif et al. Caroline L Kahn et al.
Background: Early detection is paramount when reducing incidence and mortality of colorectal cancer (CRC). Current population-based screening programs primarily use fecal immunochemical test (FIT) to allocate individuals ...
Escalated Segmental and Modified Radiation Lobectomy Dosing for Yttrium-90 Radioembolization of Liver-Dominant Metastatic Colorectal Cancer: 10-year Outcomes [0.03%] 用于肝主导的转移性结直肠癌钇-90放射栓塞治疗的剂量升级分段及改良放疗剂量：10年结果
Andrew C Gordon,Saad Abu Zahra,Muhamad Serhal et al. Andrew C Gordon et al.
Purpose: This study evaluates the safety and efficacy of escalated-dosing Yttrium-90 transarterial radioembolization (TARE) for unresectable, unablatable metastatic colorectal cancer (mCRC) to the liver. ...
Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer [0.03%] 检查淋巴结作为II期或III期结肠癌患者预后因素的数量
Hyunwook Kim,Lingjie Shen,Jeongseok Jeon et al. Hyunwook Kim et al.
Background: Lymph node (LN) examination is important for staging colorectal cancer. Examining < 12 LN has been associated with a poor prognosis. However, surgical and pathological advances have led to increase examined LN...
Treatment Adherence to Adjuvant Chemotherapy According to the New Standard 3-month CAPOX Regimen in High-risk Stage II and Stage III Colon Cancer: A Population-based Evaluation in The Netherlands [0.03%] 根据新的标准3个月CAPOX方案，高危II期和III期结肠癌患者辅助化疗的治疗依从性：来自荷兰的人群评估研究
Kim van den Berg,Felice N van Erning,Jacobus Wa Burger et al. Kim van den Berg et al.
Background: A 3-month adjuvant treatment regimen with capecitabine and oxaliplatin (CAPOX) for high-risk stage II (T4N0) and stage III (node-positive) colon cancer was implemented in the Netherlands in 2017. The IDEA tria...
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) [0.03%] 杜斯特利马布单药治疗未经治疗的II/III期dMMR/MSI-H局部晚期直肠癌患者的二期、单臂、开放标签研究(AZUR-1)
Andrea Cercek,Jean-Baptiste Bachet,Jaume Capdevila et al. Andrea Cercek et al.
Background: Colorectal cancer (CRC) had the second highest cancer mortality worldwide in 2020; nearly a third of CRCs were rectal cancers (RC). A recent study demonstrated that dostarlimab, an immune-checkpoint inhibitor,...
Does Extramural Vascular Invasion Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer? [0.03%] 肠旁血管侵犯能否预测局部晚期直肠癌新辅助治疗的疗效？
Neal Bhutiani,Mahmoud Mg Yousef,Abdelrahman Mg Yousef et al. Neal Bhutiani et al.
Introduction: Extramural vascular invasion (EMVI) is associated with distant recurrence after treatment of locogionally advanced rectal adenocarcinomas (LARCs), but its use as a marker for response to neoadjuvant therapy ...
Association Between Colorectal Cancer Primary Features and Liver Metastases Histological Growth Patterns: Inflammation on the Primary Tumor is Associated with Desmoplastic Growth Pattern [0.03%] 结直肠癌原发灶特征与肝转移病灶组织生长模式之间的关联：原发肿瘤的炎症与间质性生长模式有关
Ana Margarida Abrantes,Rui Caetano-Oliveira,Bárbara Oliveiros et al. Ana Margarida Abrantes et al.
Background: More than 50% of patients diagnosed with colorectal cancer (CRC) will develop liver metastases (CRCLM), which is the main cause of death for more than 60% of these patients. The aim of this study was to correl...
Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data [0.03%] DPYD基因分型对结肠癌氟尿嘧啶辅助治疗的影响：实际世界数据
Jatta Saarenheimo,Hugo Willför,Nesna Wahid et al. Jatta Saarenheimo et al.
Background: The application of fluoropyrimidine-based chemotherapy in colorectal cancer treatment is known to pose significant toxicity risks, which can be mitigated by tailoring treatment according to DPYD gene variants....